Segment Information - Summary of Significant Expense Categories and Consolidated Net Loss Details (Details) - USD ($) |
3 Months Ended | 9 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Jun. 30, 2026 |
Mar. 31, 2026 |
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|||||
| Research and development: | ||||||||||||
| Other expenses | [1] | $ (112,180) | $ (24,897) | $ (424,214) | $ (69,080) | |||||||
| Personnel expenses (including stock-based compensation) | (522,597) | (325,710) | (1,450,842) | (1,026,332) | ||||||||
| General and administrative | (1,870,678) | (1,020,154) | (5,330,134) | (3,399,559) | ||||||||
| Change in fair value of warrant liability | 0 | 611 | 0 | 2,071 | ||||||||
| Interest income | 68,063 | 35,512 | 233,996 | 82,901 | ||||||||
| Other income and expenses, net | [2] | 0 | (288) | 256,373 | 11,611 | |||||||
| Net loss | (3,315,513) | $ (3,323,384) | $ (3,009,051) | (1,907,176) | $ (2,444,382) | $ (2,051,085) | (9,647,948) | (6,402,643) | ||||
| GEM-AKI program Expenses [Member] | ||||||||||||
| Research and development: | ||||||||||||
| Clinical study expenses | (816,437) | (286,125) | (2,247,519) | (1,002,127) | ||||||||
| GEM-CKD Program Expenses [Member] | ||||||||||||
| Research and development: | ||||||||||||
| Clinical study expenses | 0 | (286,125) | (78,978) | (1,002,128) | ||||||||
| GEM-AKI Manufacturing Expenses [Member] | ||||||||||||
| Research and development: | ||||||||||||
| Clinical study expenses | $ (61,684) | $ 0 | $ (606,630) | $ (0) | ||||||||
| ||||||||||||
| X | ||||||||||
- Definition clinical study expenses. No definition available.
|
| X | ||||||||||
- Definition Other income and (expenses) net. No definition available.
|
| X | ||||||||||
- Definition Cost of labor directly related to good produced and service rendered. Includes, but is not limited to, payroll cost and equity-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as operating. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|